Activation of STAT1, IRF-1, and NF-κB is required for the induction of uridine phosphorylase by tumor necrosis factor-α and interferon-γ

Nucleosides, Nucleotides and Nucleic Acids

Volumn 29, Issue 4-6, 2010, Pages 488-503

  Wan, Laxiang ^a   Cao, Deliang ^b   Zeng, Jianmin ^a   Ziemba, Amy ^c   Pizzorno, Giuseppe ^a,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEVADA CANCER INSTITUTE   (United States)

Author keywords

gene expression regulation; IFN ; IRF 1; NF B; promoter analysis; STAT 1; TNF

Indexed keywords

DOXIFLURIDINE; FLUOROURACIL; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 1; MESSENGER RNA; STAT1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; URIDINE PHOSPHORYLASE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CYTOTOXICITY; ENZYME ACTIVITY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOLECULAR MECHANICS; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN BINDING; RNA ANALYSIS; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; HUMANS; INTERFERON REGULATORY FACTOR-1; INTERFERON-GAMMA; MICE; NF-KAPPA B; STAT1 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA; URIDINE PHOSPHORYLASE;

MURINAE;

EID: 77953727138     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257771003729682     Document Type: Article

References (41)

1. Pizzorno, G.; Diasio, R.B.; Cheng, Y.-C. Pyrimidine and purine antimetabolites. In: Cancer Medicine, ed. R.C. Bast et al., B.C. Decker, London, 2000, pp. 625-647.
2. Armstrong, R.D.; Diasio, R.B. Metabolism and biological activity of 5-deoxy-5-fluorouridine, a novel fluoropyrimidine. Cancer Res. 1980, 40, 3333-3338.
3. Patterson, A.V.; Zhang, H.; Moghaddam, A.;. Bicknell, R.; Talbot, D.C.; Stratford, I.J.; Harris, A.L. Increased sensitivity to the prodrug 5-deoxy-5-fluorouridine and modulation of 5-fluoro-2- deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br. J. Cancer 1995, 2, 669-675.
4. Reigner, B.; Blesch, K.; Weidekamm, E. Clinical pharmacokinetics of capecitabine. Clin. Pharmacokinet. 2001, 40, 85-104.
5. Ishikawa, T.;Utoh, M.; Sawada,N.; Nishida, M.; Fukase, Y.; Sekiguchi, F.; Ishitsuka,H. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem. Pharmacol. 1998, 55, 1091-1097.
6. Schuller, J.;Cassidy, J.; Dumont, E.; Roos, B.; Durston, S.; Banken, L.;Utoh, M.; Mori, K.; Weidekamm, E.; Reigner, B. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother. Pharmacol. 2000, 45, 291-297.
7. Cao, D.; Russell, R.L.; Zhang, D.; Leffert, J.J.; Pizzorno, G. Uridine phosphorylase (-/-) murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines. Cancer Res. 2002, 62, 2313-2317.
8. Schwartz, P.M.; Moir, R.D.; Hyde, C.M.; Turek, P.J.; Handschumacher, R.E. Role of uridine phosphorylase in the anabolism of 5-fluorouracil. Biochem. Pharmacol. 1985, 34, 3585-3589.
9. Pizzorno, G.; Cao, D.; Leffert, J.J.; Russell, R.L.; Zhang, D.; Handschumacher, R.E. Homeostatic control of uridine and the role of uridine phosphorylase: a biological and clinical update. Biochim. Biophys. Acta 2002, 1587, 133-144.
10. Wan, L.; Cao, D.; Zeng, J.; Yan, R.; Pizzorno,G.Modulation of uridine phosphorylase gene expression by tumor necrosis factor-alpha enhances the antiproliferative activity of the capecitabine intermediate 5-deoxy-5- fluorouridine in breast cancer cells. Mol. Pharmacol. 2006, 69, 1389-1395.
11. de Bruin, M.; van Capel, T.; Van der Born, K.; Kruyt, F.A.; Fukushima, M.; Hoekman, K.; Pinedo, H.M.; Peters, G.J. Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity. Br. J. Cancer 2003, 88, 957-964.
12. Merika, M.; Williams, A.J.; Chen, G.; Collins, T.; Thanos, D. Recruitment of CBP/p300 by the IFN beta enhanceosome is required for synergistic activation of transcription. Mol. Cell 1998, 1, 277-287.
13. Eda, H.; Fujimoto, K.; Watanabe, S.; Ishikawa, T.; Ohiwa, T.; Tatsuno, K.; Tanaka, Y.; Ishitsuka, H. Cytokines induce uridine phosphorylase in mouse colon 26 carcinoma cells and make the cells more susceptible to 5-deoxy-5-fluorouridine. Jpn. J. Cancer Res. 1993, 84, 341-347. (Pubitemid 23104320)
14. Eda, H.; Fujimoto, K.; Watanabe, S.; Ura, M.; Hino, A.; Tanaka, Y.; Wada, K.; Ishitsuka, H. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5-deoxy-5-fluorouridine. Cancer Chemother. Pharmacol. 1993, 32, 333-338. (Pubitemid 23207988)
15. Haraguchi, M.; Miyadera, K.; Uemura, K.; Sumizawa, T.; Furukawa, T.; Yamada, K.; Akiyama, S.; Yamada, Y. Angiogenic activity of enzymes. Nature 1994, 368, 198.
16. Toi, M.; Inada, K.;Hoshina, S.; Suzuki,H.; Kondo, S.;Tominaga, T. Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. Clin. Cancer Res. 1995, 1, 961-964.
17. Tanigawa, N.; Amaya, H.; Matsumura, M.; Katoh, Y.; Kitaoka, A.; Aotake, T.; Shimomatsuya, T.; Rosenwasser, O.A.; Iki, M. Tumor angiogenesis and expression of thymidine phosphorylase/platelet derived endothelial cell growth factor in human gastric carcinoma. Cancer Lett. 1996, 108, 281-290.
18. Kimura, H.; Konishi, K.; Nukui, T.; Kaji, M.; Maeda, K.; Yabushita, K.; Tsuji, M.; Miwa, A. Prognostic significance of expression of thymidine phosphorylase and vascular endothelial growth factor in human gastric carcinoma. J. Surg. Oncol. 2001, 76, 31-36.
19. Toi, M.; Ueno, T.; Matsumoto, H.; Saji, H.; Funata, N.; Koike, M.; Tominaga, T. Significance of thymidine phosphorylase as a marker of protumor monocytes in breast cancer. Clin. Cancer Res. 1999, 5, 1131-1137.
20. Makower, D.; Wadler, S.; Haynes, H.; Schwartz, E.L. Interferon induces thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in vivo. Clin. Cancer Res. 1997, 3, 923-929.
21. Schwartz, E.L.; Wan, E.; Wang, F.-S.; Baptiste, N. Regulation of expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in human colon carcinoma cells. Cancer Res. 1998, 58, 1551-1557.
22. Liu, M.-P.; Cao, D.-L.; Russell, R.L.; Handschumacher, R.E.; Pizzorno,G. Expression, characterization and detection of human uridine phosphorylase and identification of variant uridine phosphorolytic activity in selected human tumor. Cancer Res. 1998, 58, 5418-5424.
23. Zhang, D.; Cao, D.; Russell, R.; Pizzorno, G. p53-dependent suppression of uridine phosphorylase gene expression through direct promoter interaction. Cancer Res. 2001, 61, 6899-6905.
24. Cheshire, J.L.; Baldwin, A.S. Jr. Synergistic activation of NF-kappaB by tumor necrosis factor alpha and gamma interferon via enhanced I kappaB alpha degradation and de novo I kappaBbeta degradation. Mol. Cell Biol. 1997, 17, 6746-6754.
25. Thanos, D.; Maniatis, T. NF-kappa B: a lesson in family values. Cell 1995, 80, 529-532.
26. Shuai, K.; Schindler, C.; Prezioso, V.R.; Darnell, sJ.E. Jr. Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein. Science 1992, 258, 1808-1812.
27. Woods, M.; Wood, E.G.; Bardswell, S.C.; Bishop-Bailey, D.; Barker, S.; Wort, S.J.; Mitchell, J.A.; Warner, T.D. Role for nuclear factor-kappaB and signal transducer and activator of transcription 1/interferon regulatory factor-1 in cytokine-induced endothelin-1 release in human vascular smooth muscle cells. Mol. Pharmacol. 2003, 64, 923-931.
28. Paludan, S.R. Synergistic action of pro-inflammatory agents: cellular and molecular aspects. J. Leukoc. Biol. 2000, 67, 18-25.
29. Drew, P.D.; Franzoso, G.; Becker, K.G.; Bours, V.; Carlson, L.M.; Siebenlist, U.; Ozato, K. NF kappa B and interferon regulatory factor 1 physically interact and synergistically induce major histocompatibility class I gene expression. J. Interferon Cytokine Res. 1995, 15, 1037-1045.
30. Deb, A.; Haque, S.J.; Mogensen, T.; Silverman, R.H.; Williams, B.R. RNA-dependent protein kinase PKR is required for activation of NF-kappa B by IFN-gamma in a STAT1-independent pathway. J. Immunol. 2001, 166, 6170-6180.
31. Goto, H.; Kohno, K.; Sone, S.; Akiyama, S.; Kuwano, M.; Ono, M. Interferon gamma-dependent induction of thymidine phosphorylase/platelet-derived endothelial growth factor through gammaactivated sequence-like element in human macrophages. Cancer Res. 2001, 61, 469-473.
32. Yao, Y.; Kubota, T.; Sato, K.; Takeuchi, H.; Kitai, R.; Matsukawa, S. Interferons upregulate thymidine phosphorylase expression via JAK-STAT-dependent transcriptional activation and mRNA stabilization in human glioblastoma cells. J. NeuroOncol. 2005, 72, 217-223.
33. Zhu, G.H.; Lenzi, M.; Schwartz, E.L. The Sp1 transcription factor contributes to the tumor necrosis factor-induced expression of the angiogenic factor thymidine phosphorylase in human colon carcinoma cells. Oncogene 2002, 21, 8477-8485.
34. Chen, L.-C.; Liu, H.-P.; Li, H.-P.; Hsueh, C.; Yu, J.-S.; Liang, C.-L.; Chang, Y.-S. Thymidine phosphorylase mRNA stability and protein levels are increased through ERK-mediated cytoplasmic accumulation of hnRNP K in nasopharyngeal carcinoma cells. Oncogene 2009, 28, 1904-1915.
35. Schwartzberg, L.S.; Petak, I.; Stewart, C.; Turner, P.K.; Ashley, J.; Tillman, D.M.; Douglas, L.; Tan, M.; Billups, C.; Mihalik, R.; Weir, A.; Tauer, K.; Shope, S.; Houghton, J.A. Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon cancer: phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin. Clin. Cancer Res. 2002, 8, 2488-2498.
36. Sparano, J.A.; Wadler, S.; Liebes, L.; Robert, N.J.; Schwartz, E.L.; Dutcher, J.P. Phase I trial of cyclophosphamide, doxorubicin, and 5-fluorouracil plus interferon-alpha 2b in patients with advanced breast cancer. Cancer Res. 1993, 53, 3509-3512.
37. Tillman, D.M.; Petak, I.; Houghton, J.A. A Fas-dependent component in 5-fluorouracil/leucovorininduced cytotoxicity in colon carcinoma cells. Clin. Cancer Res. 1999, 5, 425-430.
38. Walters, R.S.; Theriault, R.L.; Booser, D.J.; Esparza, L.; Hortobagyi, G.N. Phase II study of recombinant alpha-interferon (rIFN alpha) and continuous-infusion 5-fluorouracil in metastatic breast cancer. J. Immunother. Emphasis Tumor Immunol. 1995, 18, 185-187.
39. Kurosumi, M.; Tabei, T.; Suemasu, K.; et al. Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients. Oncol. Rep. 2000, 7, 945-948.
40. Endo, M.; Shinbori, N.; Fukase, Y.; Sawada, N.; Ishikawa, T.; Ishitsuka, H.; Tanaka, Y. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5-deoxy-5- fluorouridine by cyclophosphamide in mammary tumor models. Int. J. Cancer 1999, 83, 127-134.
41. Sawada, N.; Ishikawa, T.; Sekiguchi, F.; Tanaka, Y.; Ishitsuka, H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin. Cancer Res. 1999, 5, 2948-2953.